Jennifer A. Dantzer, MD, MHS

IMPACT-PLuS investigator Jennifer A. Dantzer says predictive biomarkers and formal remission testing remain unanswered questions in peanut OIT.

IMPACT-PLuS follow-up data show 35% of children treated with peanut OIT had a reaction years later, with 5 requiring epinephrine, Jennifer Dantzer, MD, says.

IMPACT-PLuS follow-up found 80% of children treated with early-life peanut oral immunotherapy remained peanut tolerant 8 to 11 years later.